Charité - Univiversitätsmedizin Berlin
Berlin, 10117, Germany
NCT Number: NCT05572138
The aim of the study is to detect a value of muscle and organ mass measured by body impedance analysis and its correlation with the Medical Research Council (MRC) score. An MRC score ≤ 48 is defined as a diagnosis of ICU acquired weakness. The correlation of the values detected by BIA and their transfer to an MRC Score ≤ 48 will be investigated.
The knowledge gained will be used for early detection of ICUAW in order to reduce the consequences of the same.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Berlin, 10117, Germany
Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of neuromuscular organ dysfunction. It develops in approximately 40% of all ICU patients, which corresponds to at least 1.2 million patients annually in Germany. All these patients face a wide spectrum of sequelae and increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is early severe muscle atrophy, which is as high as 17% in the first days after ICU admission.
ICUAW is currently diagnosed by the MRC score, which is assessed by the sum of manual muscle strength test results in 12 muscle groups (sum score). Manual muscle testing (MMT) is not possible during the early phase in critical illness in most patients due to coma, delirium, and/or injury. In addition, there is a possible discrepancy by different observers. As a result, early detection of ICUAW may be inadequate in most patients and unreliable during critical illness.
Measurement by BIA is reproducible, so differences in measurement can be attributed to changes in clinical condition. Body impedance analysis thus demonstrates a means of objective measurement.
Thus, the study aims to counteract the long-term consequences of ICUAW through early detection of ICUAW by allowing countermeasures to be taken earlier.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Body Impedance Analysis
Time frame: till Day 30
The primary endpoint is the correlation between Skeletal muscle mass (SMM) measured by BIA and MRC score.
Time frame: till Day 30
Cross sectional area of muscle ultrasound (M. rectus femoris) and Skeletal muscle mass (SMM) measured by BIA
Time frame: till Day 30
Correlation of urea-creatinine ratio in blood with MRC score.
Time frame: till Day 30
Correlation of creatinine in blood with MRC score.
Time frame: till Day 30 or ICU discharge
achieved mobilization level during the ICU stay using the ICU Mobility Scale (IMS)
Time frame: till Day 30
Mortality during ICU stay
Time frame: till Day 30
Duration of invasive mechanical ventilator dependency
Time frame: till Day 30
Mortality during Hospital stay
Time frame: till Day 30 (till ICU discharge)
Length of stay in the ICU
Time frame: till Day 30 (till hospital discharge)
Length of stay in the hospital
Time frame: till Day 30 (till hospital discharge)
Mortality during the Hospital stay
Charite University, Berlin, Germany
Other
Body Impedance Analysis to Detect Muscle Strength Associated With ICU Acquired Weakness
Acronym: BIAMI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04612348
Critical Illness, Disease Attributes
Columbus, Ohio, United States
View Trial DetailsNCT03195127
Chronic Disease, Critical Illness
Baltimore, Maryland, United States
View Trial DetailsNCT07020637
Critical Illness, Disease Attributes
Las Vegas, Nevada, United States
View Trial DetailsNCT07579728
Critical Illness, Disease Attributes
Istanbul, Turkey (Türkiye)
View Trial Details